Biotechnology

CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase in San Francisco

December 7, 2021 5:50 PM

TUCSON, AZ / ACCESSWIRE / December 7, 2021 / Aqualung Therapeutics Corp., an early stage immunotherapeutics company which has developed an anti-inflammatory therapeutic platform for life-threatening unchecked inflammation, will be presenting at the annual Biotech Showcase in San Francisco in conjunction with the JP Morgan Healthcare conference, January 11th at 10:30am pacific time, Hilton Hotel, Franciscan C Ballroom. As one of the biggest...

Read more

Medspresso Coffee Webinar Now Available for Viewing

December 7, 2021 8:25 AM

CAPE TOWN, SA / ACCESSWIRE / December 7, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update: Medspresso™ is delighted to share the recorded version of the coffee webinar The Art, Craft, and Science of Coffee held December 01, 2021 is now available for viewing and can be...

Read more

CB Scientific, Inc. Executes Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.

December 7, 2021 6:00 AM

Partnership to provide high volume manufacturing capability and facilitate obtaining requisite government approvals ESCONDIDO, CA / ACCESSWIRE / December 7, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") announced Shenzhen Pump Medical System Co., Ltd. (SPMS), a leading Chinese developer, manufacturer, and distributor of medical equipment and devices focusing on cardiovascular diagnostic systems, has issued a formal Letter...

Read more

Marvel Biosciences to Present at the SNN Network Canada Virtual Event on Wednesday, December 8, 2021

December 3, 2021 8:00 AM

CALGARY, AB / ACCESSWIRE / December 3, 2021 / Marvel Biosciences (TSXV:MRVL), and its wholly owned subsidiary, Marvel Biotechnology Inc., today announced that it will be presenting at the SNN Network Canada Virtual Event 2021 on Wednesday, December 8th at 2:00 PM EST. President and CSO Mark Williams will be hosting the presentation and answering questions from investors. To access the live presentation, please use the following information: SNN...

Read more

Oxford Nanopore Technologies plc Announces Technology Updates

December 2, 2021 2:00 AM

OXFORD, UK / ACCESSWIRE / December 2, 2021 // Highlights include release of new "Kit 12" and R10.4 flow cells for >Q20 (>99%) raw read and around Q30 (99.9%) Duplex sequencing accuracy, and the new PromethION P2 device, a palm-sized, high-throughput sequencer that delivers the most accessible low-cost, high-output Oxford Nanopore sequencer Oxford, UK: Oxford Nanopore has provided a technology update at its Nanopore Community Meeting, describing...

Read more

Applied UV Continues Global Expansion with Airocide(R) Installations in Thailand at the Acclaimed Armed Forces Research Institute of Medical Sciences ("AFRIMS")

December 1, 2021 8:30 AM

AFRIMS to install Airocide® technology to protect visitors and staff AFRIMS is a biomedical research facility of the U.S. Army's Walter Reed Army Institute of Research MOUNT VERNON, NY / ACCESSWIRE / December 1, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology...

Read more

Edesa Biotech Marks Enrollment Milestone in Dermatitis Study

December 1, 2021 7:58 AM

TORONTO, ON / ACCESSWIRE / December 1, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 75% of the patients planned for the primary cohort of a Phase 2b clinical study evaluating the company's drug candidate, designated EB01, as a monotherapy for chronic allergic contact dermatitis. The...

Read more

Q2 Interim Report - Promising Results Published at ESMO

December 1, 2021 1:45 AM

UPPSALA, SE / ACCESSWIRE / December 1, 2021 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) SEK 000s Q2 21/22 Q2 20/21 May-Oct 21/22 May-Oct 20/21 Full year 20/21 Net sales 268 44 649 384 2,077 Operating profit (loss) -14,314 -8,285 -26,552 -16,950 -40,181 Profit (loss) for the period -14,388 -8,208 -26,613 -16,581 -39,482 Earnings per share after dilution -0.51 -0.29 -0.93 -0.59 -1.39 Significant events during the second quarter...

Read more

Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update

November 30, 2021 8:00 PM

RICHMOND HILL, ON / ACCESSWIRE / November 30, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is providing this bi-weekly update on the status of the management cease trade order granted on November 1, 2021 (the "MCTO") by its principal regulator, the Ontario Securities Commission under National Policy 12-203 Management...

Read more

Clairvoyant Therapeutics Raises More Than $3 Million in Seed Financing, Adds Bench Strength to Senior Leadership Team

November 30, 2021 8:00 AM

Institutional investor support to fund next stage investigation of psilocybin therapy as treatment for alcohol use disorder Renowned addiction specialist Mark Tyndall MD ScD joins Clairvoyant as Chief Medical Officer VANCOUVER, BC / ACCESSWIRE / November 30, 2021 / Clairvoyant Therapeutics, a Canadian biotech company focused on the development of psychedelic drug therapies for the treatment of addiction, is pleased to announce the Company has...

Read more

CB Scientific, Inc. Announces Intent to Convene a Special Meeting of the Stockholders

November 30, 2021 7:50 AM

Agenda to include matters necessary to better position the company for anticipated growth and development ESCONDIDO, CA / ACCESSWIRE / November 30, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company") has announced it will convene a Special Stockholder Meeting in order to gain approval to implement a number of significant enhancements which management believes will better position CBSC to attain its stated business objectives. As...

Read more

Oncology Pharma Research and Vision

November 30, 2021 7:30 AM

SAN FRANCISCO, CA / ACCESSWIRE / November 30, 2021 / Oncology Pharma Inc. (OTC PINK:ONPH) - Oncology Pharma, Inc. ("The Company") is a pioneering oncology company dedicated to providing the financing and the tools to license, develop, manufacture, and commercialize therapeutics. The Company has assembled a team of executives and advisors with proven multi-disciplinary expertise in the fields of oncology and therapeutics with leadership to...

Read more

American CryoStem Completes Clinical Protocol Design for Long COVID Study

November 30, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 30, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose-derived stem cell therapies today announced completion of its Phase I clinical protocol design for the treatment of Long COVID. American CryoStem anticipates that the protocol will be filed as an FDA Phase I IND in cooperation with a major US medical center in Q-1, 2022. Medical complications...

Read more

Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022

November 25, 2021 2:50 AM

LUND, SWEDEN / ACCESSWIRE / November 25, 2021 / BioInvent International (STO:BINV) Lund, Sweden - November 25, 2021 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent") Annual General Meeting in 2022 have now been appointed. The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2022: Laura Feinleib, appointed...

Read more

Hemogenyx Pharmaceuticals PLC Announces Convertible Loans Repayment

November 24, 2021 9:55 AM

Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") Convertible Loans Repayment LONDON, UK / ACCESSWIRE / November 24, 2021 / As originally announced in October 2018, Hemogenyx-Cell S.A. ("Hemogenyx-Cell") and Immugenyx LLC ("Immugenyx"), each wholly-owned subsidiaries of Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, each entered into...

Read more

Biovica Announces the Start of the TK IMPACT Trial at Washington University of St Louis

November 24, 2021 2:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / November 24, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer diagnostics, today announces initiation of the TK IMPACT study, an investigator initiated prospective clinical trial at Washington University of St Louis to evaluate the clinical utility of Biovica's blood-based biomarker assay DiviTum®TKa on monitoring practices in the care of metastatic breast cancer...

Read more

BioInvent Hosting Key Opinion Leader Webinar on BI-1206

November 23, 2021 11:35 AM

LUND, SE / ACCESSWIRE / November 23, 2021 / BioInvent International (STO:BINV) Friday, December 17 at 1 pm ET (7 pm CET) BI-1206 is a Potential Treatment for non-Hodgkin's Lymphoma and Solid Tumors BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that it will host a key...

Read more

Thermic Science Prepares Form 10 Registration Statement To File First Quarter 2022, Begins 2-Year Audit Current Filings To Become Fully-Reporting Status Meeting the Requirements Of The SEC Exchange Act Of 1934 With Subsequent Up Listings To The OTCQB and NASDAQ

November 23, 2021 10:15 AM

NASHVILLE, TN / ACCESSWIRE / November 23, 2021 / Thermic Science International Corporation, formerly known as Omnicanna Health Solutions, Inc. aka ENDOCAN CORP. (WKN: A1W61J, ISIN: US29271J1097) (OTC:ENDO), is pleased to announce that Thermic Science, working on the filing a Form 10 Registration Statement with the United States Securities and Exchange Commission pursuant to Section 12(g) of the Securities Exchange Act of 1934 and prepare for...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

November 23, 2021 9:00 AM

MOUNT VERNON, NY / ACCESSWIRE / November 23, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

American CryoStem Announces the Addition of John Schwartz, PhD to Its Advisory Board

November 23, 2021 1:00 AM

EATONTOWN, NJ / ACCESSWIRE / November 23, 2021 / American CryoStem Corporation (OTC PINK:CRYO), a leading clinical-stage biotechnology developer of adipose tissue-based cellular technologies for Regenerative and Personalized Medicine announced today that it has added John "Jay" Schwartz, PhD to its Scientific and Medical Advisory Board. Dr. Schwartz, who holds a PhD in biochemistry and molecular biology, has served as an academic researcher at...

Read more